What is the prevalence of Erythromelalgia?

Erythromelalgia is considered a rare condition, with an estimated prevalence ranging from 0.36 to 2 per 100,000 individuals, though these figures are likely underestimates due to significant diagnostic delays.

Epidemiological Overview

Because Erythromelalgia is frequently misdiagnosed as other vascular or neurological conditions, precise incidence and prevalence data remain elusive. Research published by Orphanet suggests that while the disorder is rare, it is likely more common than current clinical registries indicate. The clinical presentation of Erythromelalgia can be categorized into primary (often genetic, such as mutations in the SCN9A gene) or secondary (associated with underlying conditions like polycythemia vera or small fiber neuropathy), which complicates global counting efforts.

Demographics and Onset

The distribution of Erythromelalgia varies based on the underlying etiology. Primary Erythromelalgia often presents in childhood or adolescence, whereas secondary forms typically emerge in adulthood. Epidemiological studies suggest a female predominance in many cohorts, though this may reflect healthcare-seeking behaviors rather than true biological susceptibility. There is currently no evidence of specific geographic or ethnic clusters, as cases have been reported globally across diverse populations.

Challenges in Data Collection

The rarity of Erythromelalgia often leads to a "diagnostic odyssey," where patients visit multiple specialists before receiving an accurate diagnosis. This underdiagnosis means that official prevalence numbers often lag behind the reality of the patient population. At DiseaseMaps.org, our community of 534 members provides a vital real-world perspective; by aggregating patient-reported data, we can better visualize the burden of Erythromelalgia that traditional clinical literature may overlook. Engaging with patient-led communities helps researchers bridge the gap between clinical statistics and the lived experience of those navigating this condition.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• Orphanet: Portal for rare diseases and orphan drugs.


• NIH Genetic and Rare Diseases Information Center (GARD).


• OMIM (Online Mendelian Inheritance in Man).


• The Erythromelalgia Association (TEA).